Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer Risk Calculators: A Performance Comparison in a Contemporary Screened Cohort

Cavadas, Vítor; Osório, Luís; Sabell, Francisco; Teves, Frederico; Branco, F.; Silva-Ramos, Miguel

doi:10.1016/j.eururo.2010.06.023

Cited by 82 publications

(57 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This discrepancy suggests that urologists in Asian and Western countries likely face different situations with regard to prostate cancer. Additionally, our findings were in agreement with those of Cavadas et al, 7 who demonstrated that TRUS findings are not an independent predictor of prostate cancer. Conversely, Kawakami et al…”

supporting

confidence: 83%

“…These findings are consistent with those in previous reports. 6,7 However, after multivariate analysis, % free PSA and TRUS findings were not independent predictors of a positive initial prostate biopsy. Previous studies have found % free PSA to be an independent predictor of prostate cancer; 11,12 however, a report from Korea demonstrated that % free PSA provided no added diagnostic benefit in Korean men from 50 to 65 years old with a PSA of 4.0-10.0 ng ml…”

Section: Discussionmentioning

confidence: 99%

“…6 The Prostate Cancer Prevention Trial (PCPT) and the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators are the best known nomograms for incorporating known risk factors. 7 Additionally, the incidence of prostate cancer in men from industrialised countries has been shown to be substantially different from that in men from developing countries. 2 Therefore, nomogram models used to predict the risk of prostate cancer that were generated from male populations in industrialised countries may not be directly applicable to Chinese men.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer

Tang¹,

Chen²,

Uhlman³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

Nomograms for predicting the risk of prostate cancer developed using other populations may introduce sizable bias when applied to a Chinese cohort. In the present study, we sought to develop a nomogram for predicting the probability of a positive initial prostate biopsy in a Chinese population. A total of 535 Chinese men who underwent a prostatic biopsy for the detection of prostate cancer in the past decade with complete biopsy data were included. Stepwise logistic regression was used to determine the independent predictors of a positive initial biopsy. Age, prostate-specific antigen (PSA), prostate volume (PV), digital rectal examination (DRE) status, % free PSA and transrectal ultrasound (TRUS) findings were included in the analysis. A nomogram model was developed that was based on these independent predictors to calculate the probability of a positive initial prostate biopsy. A receiver-operating characteristic curve was used to assess the accuracy of using the nomogram and PSA levels alone for predicting positive prostate biopsy. The rate for positive initial prostate biopsy was 41.7% (223/535). The independent variables used to predict a positive initial prostate biopsy were age, PSA, PV and DRE status. The areas under the receiver-operating characteristic curve for a positive initial prostate biopsy for PSA alone and the nomogram were 79.7% and 84.8%, respectively. Our results indicate that the risk of a positive initial prostate biopsy can be predicted to a satisfactory level in a Chinese population using our nomogram. The nomogram can be used to identify and counsel patients who should consider a prostate biopsy, ultimately enhancing accuracy in diagnosing prostate cancer.

show abstract

supporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer

Tang¹,

Chen²,

Uhlman³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…The ERSPC has been externally validated in Swedish and Finnish cohorts, in which this tool discriminated between those with and without cancer but overestimated risk of positive biopsy [67]. When the ERSPC calculator was compared with the PCPT method, it was found to outperform the latter model when used for both European and North American cohorts [68][69][70].…”

Section: Integrated Prediction Of Prostate Cancer Riskmentioning

confidence: 99%

Risk-Based Prostate Cancer Screening: Who and How?

2013

View full text Add to dashboard Cite

The purpose of this review is to identify clinical risk factors for prostate cancer and to assess the utility and limitations of our current tools for prostate cancer screening. Prostate-specific antigen is the single most important factor for identifying men at increased risk of prostate cancer but is best assessed in the context of other clinical factors; increasing age, race, and family history are well-established risk factors for the diagnosis of prostate cancer. In addition to clinical risk calculators, novel tools such as multiparametric imaging, serum or urinary biomarkers, and genetic profiling show promise in improving prostate cancer diagnosis and characterization. Optimal use of existing and future tools will help alleviate the problems of overdiagnosis and overtreatment of low-risk prostate cancer without reversing the substantial mortality declines that have been achieved in the screening era.

show abstract

“…The risk calculators that predict the outcome of a biopsy (i.e., having prostate cancer or potentially aggressive prostate cancer) have been externally validated in several populations and successfully implemented in clinical practice. 38,39 Considering multiple risk factors in combination can provide patients with a more personalized risk assessment and reduce the number of unnecessary biopsies versus using PSA testing alone. However, as PSA is an important component in each of these models, eliminating PSA screening would preclude their use.…”

Section: A Possible Way Forward: Individualized Decision-makingmentioning

confidence: 99%

Prostate-specific antigen screening can be beneficial to younger and at-risk men

Roobol

Bangma

Loeb

2012

CMAJ

View full text Add to dashboard Cite

Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer Risk Calculators: A Performance Comparison in a Contemporary Screened Cohort

Cited by 82 publications

References 11 publications

A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer

A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer

Risk-Based Prostate Cancer Screening: Who and How?

Prostate-specific antigen screening can be beneficial to younger and at-risk men

Contact Info

Product

Resources

About